Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice

Diana Canetti,1 Laura Galli,1 Riccardo Lolatto,1 Silvia Nozza,2 Vincenzo Spagnuolo,1 Camilla Muccini,1 Benedetta Trentacapilli,2 Elena Bruzzesi,2 Martina Ranzenigo,2 Matteo Chiurlo,2 Antonella Castagna,1,2 Nicola Gianotti1 1Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy; 2...

Full description

Bibliographic Details
Main Authors:	Canetti D, Galli L, Lolatto R, Nozza S, Spagnuolo V, Muccini C, Trentacapilli B, Bruzzesi E, Ranzenigo M, Chiurlo M, Castagna A, Gianotti N
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-12-01
Series:	Drug Design, Development and Therapy
Subjects:	bictegravir people living with hiv plwh efficacy safety clinical practice.
Online Access:	https://www.dovepress.com/bictegraviremtricitabinetenofovir-alafenamide-treatment-efficacy-and-t-peer-reviewed-fulltext-article-DDDT

Similar Items

Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
by: Januszka JE, et al.
Published: (2023-11-01)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023-12-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-07-01)

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form
by: Tej Kumar Kokkirala, et al.
Published: (2019-12-01)

Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
by: Giuseppe Vittorio De Socio, et al.
Published: (2023-12-01)

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
by: Daniele Armenia, et al.
Published: (2022-09-01)

Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China
by: Linghong Kong, et al.
Published: (2023-08-01)

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort
by: Alessandro Lazzaro, et al.
Published: (2023-05-01)

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
by: Baptiste Sellem, et al.
Published: (2023-03-01)

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis
by: Abdulmajeed Alharbi
Published: (2023-05-01)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
by: Ranzenigo M, et al.
Published: (2022-06-01)

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
by: Ranzenigo M, et al.
Published: (2022-10-01)

A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia
by: Kanak Parmar, et al.
Published: (2023-01-01)

Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study
by: Monica Basso, et al.
Published: (2023-08-01)

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
by: Franco Maggiolo, et al.
Published: (2022-11-01)

Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review
by: Kazuhiro Ishikawa, et al.
Published: (2023-07-01)

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
by: Bruno Emond, et al.
Published: (2021-06-01)

Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)
by: Anne M. Masich, et al.
Published: (2023-04-01)

Three-step synthetic procedure to prepare dolutegravir, cabotegravir, and bictegravir
by: Xianheng Wang, et al.
Published: (2022-04-01)

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model
by: Haneesha Mohan, et al.
Published: (2022-08-01)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
by: Yongquan Peng, et al.
Published: (2023-11-01)

Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
by: Jen-Yu Hsu, et al.
Published: (2024-03-01)

Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
by: Yinghua Wei, et al.
Published: (2023-11-01)

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
by: Hill L, et al.
Published: (2018-10-01)

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
by: Cao Jing, et al.
Published: (2023-06-01)

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
by: Inés Mendoza, et al.
Published: (2023-01-01)

Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide
by: Ling-Ya Chen, et al.
Published: (2023-06-01)

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults
by: Inés Mendoza, et al.
Published: (2023-01-01)

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsResearch in context
by: Paul E. Sax, et al.
Published: (2023-05-01)

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
by: Mao-Song Tsai, et al.
Published: (2023-01-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
by: Chang Huang, et al.
Published: (2023-03-01)

Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort
by: Alessandro Lazzaro, et al.
Published: (2021-12-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
by: Lin Gan, et al.
Published: (2023-10-01)

An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1
by: An Liu, et al.
Published: (2022-11-01)

Thyroid Diseases and Thyroid Asymptomatic Dysfunction in People Living With HIV
by: Cristina Micali, et al.
Published: (2022-09-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

IL-10 and IL-17 as Progression Markers of Syphilis in People Living with HIV: A Systematic Review
by: Adriana Hernández-Pliego, et al.
Published: (2022-10-01)

A structural equation model of perceived and internalized stigma, depression, and suicidal status among people living with HIV/AIDS
by: Chengbo Zeng, et al.
Published: (2018-01-01)

Three sides of a coin in the life of people living with HIV (PLWH)
by: Deepika Cecil Khakha, et al.
Published: (2015-01-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)